Laboratory of Applied Pharmacokinetics, Keck School of Medicine, University of Southern California, Children's Hospital of Los Angeles, MS # 51, 4650 Sunset Blvd, Los Angeles, CA, 90027, USA,
Clin Pharmacokinet. 2014 May;53(5):397-407. doi: 10.1007/s40262-014-0141-6.
This report examined the role of digitalis pharmacokinetics in helping to guide therapy with digitalis glycosides with regard to converting atrial fibrillation (AF) or flutter to regular sinus rhythm (RSR). Pharmacokinetic models of digitoxin and digoxin, containing a peripheral non-serum effect compartment, were used to analyze outcomes in a non-systematic literature review of five clinical studies, using the computed concentrations of digitoxin and digoxin in the effect compartment of these models in an analysis of their outcomes. Four cases treated by the author were similarly examined. Three literature studies showed results no different from placebo. Dosage regimens achieved ≤11 ng/g in the model's peripheral compartment. However, two other studies achieved significant conversion to RSR. Their peripheral concentrations were 9-14 ng/g. In the four patients treated by the author, three converted using classical clinical titration with incremental doses, plus therapeutic drug monitoring and pharmacokinetic guidance from the models for maintenance dosage. They converted at peripheral concentrations of 9-18 ng/g, similar to the two studies above. No toxicity was seen. Successful maintenance was achieved, using the models and their pharmacokinetic guidance, by giving somewhat larger than average recommended dosage regimens in order to maintain peripheral concentrations present at conversion. The fourth patient did not convert, but only reached peripheral concentrations of 6-7 ng/g, similar to the studies in which conversion was no better than placebo. Pharmacokinetic analysis and guidance play a highly significant role in converting AF to RSR. To the author's knowledge, this has not been specifically described before. In my experience, conversion of AF or flutter to RSR does not occur until peripheral concentrations of 9-18 ng/g are reached. Results in the four cases correlated well with the literature findings. More work is needed to further evaluate these provocative findings.
本报告探讨了数字化药代动力学在指导洋地黄糖苷治疗中的作用,特别是在将心房颤动(AF)或扑动转为规则窦性节律(RSR)方面。使用包含外周非血清效应室的地高辛和去乙酰毛花苷药代动力学模型,对五项临床研究的非系统性文献综述进行了分析,利用这些模型中效应室的地高辛和去乙酰毛花苷计算浓度来分析其结果。作者还对四个案例进行了类似的检查。三项文献研究结果与安慰剂无差异。治疗方案在模型的外周室中达到≤11ng/g。然而,另外两项研究则取得了显著的 RSR 转化效果。其外周浓度为 9-14ng/g。在作者治疗的四个患者中,有三个患者通过经典的临床滴定法增加剂量,以及治疗药物监测和模型的药代动力学指导来维持剂量,成功转化。他们的外周浓度为 9-18ng/g,与上述两项研究相似。未观察到毒性。通过使用模型及其药代动力学指导,给予略高于平均推荐剂量方案,以维持转化时存在的外周浓度,成功实现了维持治疗。第四位患者没有转化,但其外周浓度仅达到 6-7ng/g,与转化效果不比安慰剂更好的研究相似。药代动力学分析和指导在将 AF 转为 RSR 方面发挥了非常重要的作用。据作者所知,这之前尚未有具体描述。根据作者的经验,只有当外周浓度达到 9-18ng/g 时,AF 或扑动才会转为 RSR。四个案例的结果与文献发现高度相关。需要进一步开展更多工作来进一步评估这些有启发性的发现。